Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study
Open Access
- 2 June 2016
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 115 (1) , 20-24
Abstract
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.Keywords
This publication has 21 references indexed in Scilit:
- Outcomes and endpoints in trials of cancer treatment: the past, present, and futureThe Lancet Oncology, 2015
- Sorafenib: from literature to clinical practiceAnnals of Oncology, 2013
- Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512PLOS ONE, 2012
- Genotype-Dependent Sensitivity of Uveal Melanoma Cell Lines to Inhibition of B-Raf, MEK, and Akt Kinases: Rationale for Personalized TherapyInvestigative Ophthalmology & Visual Science, 2011
- Measurement error in the timing of events: effect on survival analyses in randomized clinical trialsClinical Trials, 2010
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Very Long-Term Prognosis of Patients with Malignant Uveal MelanomaInvestigative Ophthalmology & Visual Science, 2003
- Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials GroupStatistics in Medicine, 1998
- The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigueJournal of Psychosomatic Research, 1995
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.Journal of Clinical Oncology, 1993